INTRODUCTION {#s1}
============

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the intestinal tract that causes relapse and remission, and is usually classified into two clinical syndromes: ulcerative colitis (UC) and Crohn\'s disease (CD) \[[@R1]\]. Although the etiology of IBD is unclear, twin and familial aggregation studies have demonstrated roles for genetic factors. Genetic epidemiology studies have indicated that UC and CD are polygenic disorders, and that genetic susceptibility factors play an important role in the pathogenesis of these two diseases \[[@R2]\]. Previous studies identified several IBD susceptibility genes, including *nucleotide oligomerization domain 2 (NOD2)*, *interleukin-10 (IL-10)*, *IL-23*, and *ATG16L1* \[[@R3], [@R4]\]. Genome-wide association studies (GWAS) have implicated that genes were involved in both UC and CD, indicating a partly shared pathogenesis \[[@R5], [@R6]\].

*Myosin IXB* (*MYO9B*) encodes a single-headed processive myosin that is a member of the class IX myosin family \[[@R7]\]. MY09B is expressed in various tissues and cell types, including human intestinal epithelial cells \[[@R8]\]. Studies using a rat model shown that overexpression of MYO9B results in actin filament-related morphologic changes in epithelial cells \[[@R9]\]. A previous Dutch study first suggested *MYO9B* as a susceptibility gene for celiac disease \[[@R10]\]. *MYO9B* lies on chromosome 19p13.1, which has been linked to both celiac disease \[[@R11]\] and IBD \[[@R12]\]. Autoimmune-related disorders may possess some common genetic susceptibility factors \[[@R13]\]. Furthermore, *MYO9B* has been shown to be associated with IBD \[[@R12]\]. Therefore, *MYO9B* may be a candidate susceptibility gene for IBD.

Recently, numerous studies investigated associations between *MYO9B* gene polymorphisms and IBD susceptibility, but with discordant results \[[@R14]-[@R21]\]. The clinical heterogeneity, different ethnic populations and small sample sizes of previous studies may have contributed to these disparities. To overcome these limitations and resolve inconsistencies, we performed a meta-analysis of the contradictory results from these relevant studies to clarify the associations between *MY09B* gene polymorphisms and risk of IBD, CD and UC.

RESULTS {#s2}
=======

Characteristics of the included studies {#s2_1}
---------------------------------------

A total of 47 papers were identified after our initial search. After removing duplicates and screening the titles and abstracts, 37 papers were removed. Therefore, 10 papers were selected for further full text review; two papers \[[@R22], [@R23]\] were excluded, because they did not investigate the associations between *MY09B* gene polymorphisms and IBD, CD or UC. We finally identified eight eligible papers \[[@R14]-[@R21]\] including ten studies (8,975 cases and 9,482 controls) in this meta-analysis. Selection for included studies was presented in Figure [1](#F1){ref-type="fig"}. The characteristics of these included studies are summarized in Table [1](#T1){ref-type="table"}. These studies were published from 2006 to 2014. The number for each genotype about five SNPs of *MY09B* was showed [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Five SNPs within *MY09B* gene were investigated, including rs1545620, rs962917, rs1457092, rs2305764 and rs2305767. Genotype distributions of the controls about rs1545620 in one study \[[@R17]\] did not conform to HWE \[[@R17]\] (*P* = 0.002). The NOS scores of all included studies ranged from 5 to 7 stars, which suggested they were studies of high methodological quality. Six papers were carried out in Caucasian populations \[[@R14]-[@R16], [@R18], [@R20], [@R21]\], and two in Asian populations \[[@R17], [@R19]\].

###### Characteristics of included studies

  Author and year       Country        Ethnicity   Numbers                    Polymorphisms                                      HWE values                          Genotype methods   NOS score
  --------------------- -------------- ----------- --------- ----- ---------- -------------------------------------------------- ----------------------------------- ------------------ -----------
                                                   UC        CD    Controls                                                                                                             
  Hu_2014               China          Asian       235       207   402        rs962917,rs1545620                                 0.252, 0.002                        PCR                7
  Shi_2011              China          Asian       245       NA    300        rs1545620                                          0.310                               PCR                6
  Wolters_2011          Canada         Caucasian   603       754   924        rs962917,rs1457092,rs1545620,rs2305764,rs2305767   0.971, 0.971, 0.992, 0.992, 0.995   TaqMan             6
  Cooney_2009           UK             Caucasian   650       652   1190       rs1457092,rs1545620,rs2305764,rs2305767            0.988, 0.977, 0.987, 0.993          MALDI-TOF          6
  Latiano_2008          Italy          Caucasian   658       549   674        rs962917,rs1545620,rs2305764                       0.101, 0.114, 0.107                 PCR                5
  Nunez_2007            Spain          Caucasian   677       627   990        rs1457092,rs2305764,rs2305767                      0.584, 0.772, 0.051                 NA                 7
  van Bodegraven_2006   Dutch          Caucasian   290       298   1624       rs1457092,rs1545620,rs2305764,rs2305767            0.992, 0.992, 0.995, 0.991          TaqMan             6
  van Bodegraven_2006   UK             Caucasian   580       735   2371       rs1457092,rs1545620,rs2305764,rs2305767            0.994, 0.997, 0.986, 0.980          TaqMan             6
  van Bodegraven_2006   Canada/Italy   Caucasian   650       164   445        rs1457092,rs1545620,rs2305764,rs2305767            0.969, 0.960,0.994, 1.000           TaqMan             6
  Amundsen_2006         Norway         Caucasian   308       149   562        rs1457092,rs2305764,rs2305767                      0.974, 0.972, 0.960                 NA                 6

Abbreviations: CD, Crohn\'s disease; UC, ulcerative disease; NA, not available; NOS, Newcastle--Ottawa scale.

![Selection for eligible studies included in this meta-analysis](oncotarget-07-58862-g001){#F1}

Meta-analysis of rs1545620 {#s2_2}
--------------------------

Six papers \[[@R15]-[@R19], [@R21]\] including eight studies with 7,214 cases and 7,929 controls examined rs1545620 polymorphism. As shown in Table [2](#T2){ref-type="table"}, rs1545620 polymorphism was associated with a decreased risk of IBD in recessive model (CC *vs*. AA+AC: OR, 0.62; 95% CI, 0.45-0.84, *P* = 0.002, Figure [2](#F2){ref-type="fig"}); however, our study did not find rs1545620 was associated with UC or CD risk. Stratification analyses were conducted according to ethnicity. The results indicated that rs1545620 polymorphism was also significantly associated with a decreased risk of IBD among Caucasian populations in recessive model (CC *vs*. AA+AC: OR, 0.48; 95% CI, 0.38-0.62, *P* \< 0.001). We did not find rs1545620 was related with UC or CD risk in Caucasian or Asian populations. By exclusion of one Chinese study that did not conform to HWE \[[@R17]\], the pooled estimates of the remaining studies also showed that rs1545620 polymorphism might decrease the risk of IBD (CC *vs*. AA+AC: OR, 0.53; 95% CI, 0.41-0.69, *P* \< 0.001) (Table [3](#T3){ref-type="table"}), suggesting that the results of this SNP was stable. The power analysis showed that our study has a power of 99% to detect the effects of rs1545620 polymorphism on IBD susceptibility, assuming an OR of 0.62. The false positive report probability (FPRP) of four genetic models were less than 0.5, indicating our data about this polymorphism was trustworthy.

###### Meta-analysis of associations between the rs1545620 polymorphism and IBD, UC, CD

  Disease   Comparison     Populations   Studies            OR (95% CI)       *P*-value   *P* for heterogeneity   Model   *I*^2^ (%)   P~Begger~P~Egger~ for Publication bias
  --------- -------------- ------------- ------------------ ----------------- ----------- ----------------------- ------- ------------ ----------------------------------------
  IBD       C vs. A        Overall       8                  0.95(0.86,1.06)   0.391       \<0.001                 R       78.4         0.322/0.568
                           Caucasian     6                  0.94(0.83,1.06)   0.301       \<0.001                 R       83.2         Na/Na
            Asian          2             1.03 (0.81,1.32)   0.793             0.167       F                       47.6    Na/Na        
            CC vs. AA+AC   Overall       8                  0.62(0.45,0.84)   0.002       \<0.001                 R       94.8         0.083/0.169
                           Caucasian     6                  0.48(0.38,0.62)   \<0.001     \<0.001                 R       90.4         Na/Na
            Asian          2             1.36(0.84,2.20)    0.212             0.032       R                       78.1    Na/Na        
            CC+AC vs. AA   Overall       8                  0.91(0.78,1.08)   0.287       0.001                   R       72.0         0.805/0.723
                           Caucasian     6                  0.91(0.78,1.05)   0.199       0.007                   R       68.8         Na/Na
            Asian          2             1.49(0.30,7.48)    0.625             0.003       R                       88.9    Na/Na        
            CC vs. AA      Overall       8                  0.92(0.72,1.18)   0.527       \<0.001                 R       81.7         0.458/0.412
                           Caucasian     6                  0.88(0.68,1.14)   0.348       \<0.001                 R       83.5         Na/Na
                           Asian         2                  1.51(0.33,6.90)   0.596       0.005                   R       87.3         Na/Na
  CD        C vs. A        Overall       7                  0.95(0.85,1.06)   0.335       0.006                   R       67.1         0.881/0.709
                           Caucasian     6                  0.94(0.84,1.07)   0.362       0.003                   R       72.5         Na/Na
                           Asian         1                  0.97(0.75,1.27)   0.842       Na                      Na      Na           Na/Na
            CC vs. AA+AC   Overall       7                  0.96(0.81,1.13)   0.607       0.010                   R       64.3         0.652/0.373
                           Caucasian     6                  0.95(0.78,1.15)   0.572       0.006                   R       69.4         Na/Na
                           Asian         1                  1.04(0.74,1.46)   0.807       Na                      Na      Na           Na/Na
            CC+AC vs. AA   Overall       7                  0.91(0.83,1.01)   0.069       0.145                   F       37.2         0.881/0.754
                           Caucasian     6                  0.91(0.79,1.05)   0.217       0.096                   R       46.6         Na/Na
                           Asian         1                  0.81(0.48,1.37)   0.434       Na                      Na      Na           Na/Na
            CC vs. AA      Overall       7                  0.89(0.71,1.13)   0.346       0.004                   R       68.5         0.881/0.827
                           Caucasian     6                  0.90(0.70,1.17)   0.425       0.002                   R       73.3         Na/Na
                           Asian         1                  0.85(0.49,1.45)   0.545       Na                      Na      Na           Na/Na
  UC        C vs. A        Overall       8                  0.91(0.81,1.02)   0.108       0.001                   R       71.4         0.805/0.758
                           Caucasian     6                  0.92(0.80,1.06)   0.237       \<0.001                 R       79.2         Na/Na
                           Asian         2                  0.87(0.72,1.05)   0.141       0.749                   F       0.0          Na/Na
            CC vs. AA+AC   Overall       8                  0.89(0.73,1.08)   0.247       0.001                   R       73.0         0.216/0.642
                           Caucasian     6                  0.91(0.74,1.12)   0.378       0.001                   R       74.8         Na/Na
                           Asian         2                  0.58(0.16,2.08)   0.405       0.013                   R       83.6         Na/Na
            CC+AC vs. AA   Overall       8                  0.88(0.76,1.01)   0.073       0.029                   R       55.2         0.621/0.253
                           Caucasian     6                  0.89(0.75,1.05)   0.163       0.021                   R       62.3         Na/Na
                           Asian         2                  0.80(0.53,1.19)   0.270       0.161                   F       49.1         Na/Na
            CC vs. AA      Overall       8                  0.79(0.60,1.03)   0.078       \<0.001                 R       76.7         0.621/0.340
                           Caucasian     6                  0.85(0.64,1.14)   0.278       \<0.001                 R       79.8         Na/Na
                           Asian         2                  0.49(0.22,1.10)   0.085       0.130                   F       56.3         Na/Na

\* Bold values are statistically significant (P \< 0.05). Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; CD, Crohn\'s disease; UC, ulcerative disease; IBD, inflammatory bowel disease; F, fixed effects model; R, random effects model; Na, not available.

###### Meta-analysis of the association between the rs1545620 polymorphism and IBD, UC, CD susceptibility after excluding one study (Hu et al.)

  Disease   Comparison     Model   OR(95%CI)         *P*       *I*^2^ (%)   P for heterogeneity
  --------- -------------- ------- ----------------- --------- ------------ ---------------------
  IBD       C vs. A        R       0.96(0.85,1.08)   0.473     81.5         \<0.001
            CC vs. AA+AC   R       0.53(0.41,0.69)   \<0.001   91.5         \<0.001
            CC+AC vs. AA   R       0.94(0.79,1.12)   0.470     74.2         0.001
            CC vs. AA      R       0.95(0.72,1.25)   0.720     84.1         \<0.001
  CD        C vs. A        R       0.94(0.84,1.07)   0.362     72.5         0.003
            CC vs. AA+AC   R       0.95(0.78,1.15)   0.572     69.4         0.006
            CC+AC vs. AA   R       0.91(0.79,1.05)   0.217     46.6         0.096
            CC vs. AA      R       0.90(0.70,1.17)   0.425     73.7         0.002
  UC        C vs. A        R       0.91(0.81,1.03)   0.152     75.4         \<0.001
            CC vs. AA+AC   R       0.87(0.70,1.08)   0.218     76.1         \<0.001
            CC+AC vs. AA   R       0.90(0.78,1.04)   0.147     55.0         0.038
            CC vs. AA      R       0.80(0.60,1.07)   0.136     79.5         \<0.001

\* Bold values are statistically significant (*P* \< 0.05). Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; CD, Crohn\'s disease; UC, ulcerative disease; IBD, inflammatory bowel disease; F, fixed effects model; R, random effects model.

![Forest plot shows odds ratio for associations between the rs1545620 polymorphism and IBD (CC *vs.* AA+AC)](oncotarget-07-58862-g002){#F2}

Meta-analysis of rs962917 {#s2_3}
-------------------------

Three studies \[[@R16], [@R17], [@R21]\] with 2,993 cases and 2,005 controls investigated rs962917 polymorphism. As shown in Table [4](#T4){ref-type="table"}, rs962917 polymorphism was associated with an increased risk of IBD. Stratification analyses of ethnicity also indicated that rs962917 polymorphism was significantly associated with the increased risk of IBD among Caucasian populations. We also found rs962917 was related with UC or CD risk (AA *vs*. GG+GA: OR, 1.24; 95% CI, 1.07-1.44, *P* = 0.005, Figure [3](#F3){ref-type="fig"}), especially among Caucasian populations, but not Asian populations. We did not perform sensitivity analyses, because only three studies investigated rs962917 polymorphism. Due to limited studies, we did not conduct Egger\'s and Begg\'s tests in stratification analyses of ethnicity. Both Egger\'s and Begg\'s tests revealed that there was no obvious publication bias in overall analysis for rs962917 polymorphism. The power of this meta-analysis about rs962917 polymorphism ranged from 0.57 to 0.97.

The FPRP of four genetic models was less than 0.5, indicating our data about this polymorphism was trustworthy.

###### Meta-analysis of associations between the rs962917 polymorphism and IBD, UC, CD

  Disease   Comparison     Populations   Studies           OR (95% CI)       *P*-value   *P* for heterogeneity   Model   *I*^2^ (%)   P~Begger~/P~Egger~ for Publication bias
  --------- -------------- ------------- ----------------- ----------------- ----------- ----------------------- ------- ------------ -----------------------------------------
  IBD       A vs. G        Overall       3                 1.13(1.04,1.23)   0.003       0.667                   F       0.0          0.602/0.400
                           Caucasian     2                 1.15(1.05,1.26)   0.002       0.727                   F       0.0          Na/Na
            Asian          1             1.04(0.84,1.29)   0.695             Na          Na                      Na      Na/Na        
            AA vs. GG+GA   Overall       3                 1.26(1.10,1.43)   \<0.001     0.130                   F       51.1         0.117/0.595
                           Caucasian     2                 1.28(1.11,1.48)   0.001       0.055                   R       72.9         Na/Na
            Asian          1             1.16(0.88,1.52)   0.285             Na          Na                      Na      Na/Na        
            AA+GA vs. GG   Overall       3                 1.08(0.94,1.25)   0.281       0.273                   F       23.0         0.602/0.460
                           Caucasian     2                 1.12(0.96,1.30)   0.148       0.467                   F       0.0          Na/Na
            Asian          1             0.76(0.45,1.26)   0.284             Na          Na                      Na      Na/Na        
            AA vs. GG      Overall       3                 1.31(1.10,1.58)   0.003       0.118                   F       53.2         0.602/0.445
                           Caucasian     2                 1.40(1.15,1.70)   0.001       0.335                   F       53.2         Na/Na
                           Asian         1                 0.83(0.49,1.40)   0.481       Na                      Na      Na           Na/Na
  UC        A vs. G        Overall       3                 1.12(1.01,1.24)   0.025       0.426                   F       0.0          0.602/0.830
                           Caucasian     2                 1.12(1.00,1.24)   0.048       0.199                   F       39.3         Na/Na
                           Asian         1                 1.15(0.89,1.49)   0.279       Na                      Na      Na           Na/Na
            AA vs. GG+GA   Overall       3                 1.30(0.97,1.74)   0.075       0.037                   R       69.7         0.602/0.415
                           Caucasian     2                 1.33(0.83,2.13)   0.243       0.010                   R       84.8         Na/Na
                           Asian         1                 1.28(0.93,1.77)   0.132       Na                      Na      Na           Na/Na
            AA+GA vs. GG   Overall       3                 1.06(0.89,1.25)   0.508       0.884                   F       0.0          0.117/0.068
                           Caucasian     2                 1.07(0.89,1.25)   0.443       0.921                   F       0.0          Na/Na
                           Asian         1                 0.91(0.49,1.71)   0.772       Na                      Na      Na           Na/Na
            AA vs. GG      Overall       3                 1.29(1.04,1.30)   0.020       0.151                   F       47.1         0.602/0.800
                           Caucasian     2                 0.98(0.83,1.15)   0.169       0.071                   R       69.2         Na/Na
                           Asian         1                 0.83(0.66,1.04)   0.135       Na                      Na      Na           Na/Na
  CD        A vs. G        Overall       3                 1.12(1.00,1.28)   0.044       0.289                   F       19.3         0.117/0. 107
                           Caucasian     2                 1.17(1.05,1.30)   0.005       0.703                   F       0.0          Na/Na
                           Asian         1                 0.94(0.72,1.22)   0.622       Na                      Na      Na           Na/Na
            AA vs. GG+GA   Overall       3                 1.24(1.07,1.44)   0.005       0.310                   F       14.7         0.602/0.989
                           Caucasian     2                 1.30(1.10,1.54)   0.002       0.339                   F       0.0          Na/Na
                           Asian         1                 1.03(0.74,1.44)   0.846       Na                      Na      Na           Na/Na
            AA+GA vs. GG   Overall       3                 1.04(0.78,1.40)   0.780       0.099                   R       56.8         0.602/0.476
                           Caucasian     2                 1.14(0.96,1.37)   0.142       0.294                   F       9.1          Na/Na
                           Asian         1                 0.63(0.35,1.14)   0.128       Na                      Na      Na           Na/Na
            AA vs. GG      Overall       3                 1.21(0.83,1.76)   0.323       0.074                   R       61.7         0.602/0.179
                           Caucasian     2                 1.43(1.14,1.80)   0.002       0.901                   F       0.0          Na/Na
                           Asian         1                 0.83(0.66,1.04)   0.194       Na                      Na      Na           Na/Na

\* Bold values are statistically significant (***P*** \< 0.05). Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; CD, Crohn\'s disease; UC, ulcerative disease; IBD, inflammatory bowel disease; F, fixed effects model; R, random effects model; Na, not available.

![Forest plot shows odds ratio for the associations between rs962917 and CD(AA *vs.* GG+GA)](oncotarget-07-58862-g003){#F3}

Meta-analysis of rs1457092, rs2305764, rs2305767 {#s2_4}
------------------------------------------------

Five papers \[[@R14], [@R15], [@R18], [@R20], [@R21]\] including seven studies with 7,137 cases and 8,106 controls examined rs1457092 polymorphism; six papers \[[@R14]-[@R16], [@R18], [@R20], [@R21]\] including eight studies with 8,304 cases and 8,780 controls studied rs2305764 polymorphism; five papers \[[@R14], [@R15], [@R18], [@R20], [@R21]\] including seven studies with 7,137 cases and 8,106 controls studied rs2305767 polymorphism. For these three SNPs, we did not perform stratification analyses due to lack of data. As shown in Table [5](#T5){ref-type="table"}, we found rs1457092 increased the risk of IBD (AA *vs*. CC+CA: OR, 1.20; 95% CI, 1.05-1.38, *P* = 0.009, Figure [4a](#F4){ref-type="fig"}) or UC (Figure [4b](#F4){ref-type="fig"}), but not CD. For rs2305764, we also found rs2305764 increased the risk of IBD in recessive model (AA *vs*. GG+GA: OR, 1.14; 95% CI, 1.00-1.30, *P* = 0.045, Figure [4c](#F4){ref-type="fig"}). With regard to rs2305767, our results suggested rs2305767 was associated with a decreased risk of UC (GG+AG *vs*. AA: OR, 0.84; 95% CI, 0.72-0.97, *P* = 0.020, Figure [4d](#F4){ref-type="fig"}), but not associated with IBD and CD risk. The power analysis showed that the power of this meta-analysis with regard to rs1457092, rs2305764, rs2305767 polymorphisms was greater than 0.95. The FPRP of genetic models were less than 0.5, indicating our data about these polymorphisms was trustworthy.

###### Meta-analysis of associations between rs1457092, rs2305764, rs2305767 polymorphisms and IBD, UC, CD

  Polymorphism   Comparison     Disease   Studies           OR (95% CI)       *P*-value   *P* for heterogeneity   Model   *I*^2^ (%)    P~Begger~P~Egger~ for Publication bias
  -------------- -------------- --------- ----------------- ----------------- ----------- ----------------------- ------- ------------- ----------------------------------------
  rs1457092      A vs. C        IBD       7                 1.11(1.01,1.21)   0.029       0.001                   R       73.1          0.652/0.837
                                UC        7                 1.15(1.08,1.22)   \<0.001     0.120                   F       40.7          0.293/0.711
                 CD             7         1.05(0.93,1.19)   0.402             0.001       R                       73.3    0.652/0.977   
                 AA vs. CC+CA   IBD       7                 1.20(1.05,1.38)   0.009       0.056                   R       51.2          0.652/0.822
                                UC        7                 1.27(1.13,1.42)   \<0.001     0.193                   F       30.8          0.453/0.413
                 CD             7         0.92(0.54,1.55)   0.745             \<0.001     R                       94.6    0.099/0.104   
                 AA+CA vs. CC   IBD       7                 1.16(1.06,1.26)   0.001       0.287                   F       18.7          0.453/0.868
                                UC        7                 1.16(1.06,1.28)   0.001       0.204                   F       30.9          0.453/0.989
                 CD             7         1.05(0.90,1.24)   0.528             0.003       R                       69.8    0.881/0.918   
                 AA vs. CC      IBD       7                 1.25(1.04,1.51)   0.018       0.004                   R       68.2          0.652/0.851
                                UC        7                 1.34(1.18,1.51)   \<0.001     0.128                   F       39.6          0.176/0.532
                                CD        7                 1.13(0.89,1.42)   0.316       0.007                   R       66.4          0.881/0.984
  rs2305764      A vs. G        IBD       8                 1.06(0.99,1.14)   0.084       0.026                   R       56.1          1.000/0.918
                                UC        8                 0.97(0.71,1.34)   0.867       \<0.001                 R       96.9          0.138/0.688
                                CD        8                 0.71(0.45,1.13)   0.150       \<0.001                 R       98.3          0.322/0.166
                 AA vs. GG+GA   IBD       8                 1.14(1.00,1.30)   0.045       0.020                   R       57.8          0.621/0.861
                                UC        8                 1.01(0.69,1.47)   0.966       \<0.001                 R       92.1          0.048/0.054
                                CD        8                 0.94(0.67,1.33)   0.739       \<0.001                 R       86.6          0.621/0.084
                 AA+GA vs. GG   IBD       8                 1.05(0.98,1.12)   0.145       0.134                   F       37.0          0.458/0.853
                                UC        8                 0.95(0.63,1.43)   0.800       \<0.001                 R       96.2          0.805/0.495
                                CD        8                 0.66(0.35,1.26)   0.209       \<0.001                 R       98.2          0.322/0.407
                 AA vs. GG      IBD       8                 1.15(0.99,1.34)   0.061       0.015                   R       59.6          0.621/0.993
                                UC        8                 0.98(0.58,1.63)   0.928       \<0.001                 R       94.8          0.048/0.080
                                CD        8                 0.83(0.53,1.30)   0.413       \<0.001                 R       90.9          0.621/0.068
  rs2305767      G vs. A        IBD       7                 0.92(0.83,1.02)   0.113       \<0.001                 R       79.1          0.652/0.964
                                UC        7                 0.89(0.80,0.99)   0.032       0.005                   R       67.8          0.652/0.577
                                CD        7                 0.98(0.89,1.07)   0.622       0.024                   R       58.9          0.652/0.379
                 GG vs. AA+AG   IBD       7                 0.91(0.78,1.06)   0.240       0.004                   R       68.5          0.453/0.644
                                UC        7                 0.89(0.77,1.03)   0.124       0.089                   R       45.3          0.881/0.468
                                CD        7                 1.00(0.90,1.11)   0.972       0.145                   F       37.1          0.293/0.259
                 GG+AG vs. AA   IBD       7                 0.88(0.77,1.01)   0.067       0.002                   R       71.9          0.881/0.837
                                UC        7                 0.84(0.72,0.97)   0.020       0.009                   R       64.7          0.881/0.441
                                CD        7                 0.98(0.89,1.07)   0.601       0.119                   F       40.7          0.881/0.500
                 GG vs. AA      IBD       7                 0.85(0.69,1.05)   0.134       \<0.001                 R       77.6          0.453/0.937
                                UC        7                 0.81(0.66,0.99)   0.039       0.014                   R       62.4          0.881/0.743
                                CD        7                 0.96(0.79,1.17)   0.675       0.029                   R       57.2          0.453/0.351

\* Bold values are statistically significant (P \< 0.05). Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; CD, Crohn\'s disease; UC, ulcerative disease; IBD, inflammatory bowel disease; F, fixed effects model; R, random effects model.

![Forest plot shows odds ratio for the associations\
**a.** between rs1457092 polymorphism and risk of IBD (AA ***vs.*** CC+CA); **b.** between rs1457092 polymorphism and risk of UC (AA *vs*. CC+CA); **c.** between the rs2305764 polymorphism and risk of IBD (AA *vs*. GG+GA); **d.** between rs2305767 polymorphism and risk of UC (GG+AG *vs*. AA).](oncotarget-07-58862-g004){#F4}

Sensitivity analysis and publication bias {#s2_5}
-----------------------------------------

We assessed sensitivity by omitting each study once at a time in every genetic model for these five SNPs. The pooled ORs for the effects of rs962917, rs1457092, rs2305764 and rs2305767 on the risk for IBD or CD or UC indicated that our data were stable and trustworthy about these four SNPs. However, we found pooled ORs for the effect of rs1545620 on the risk for IBD (Figure [5a](#F5){ref-type="fig"}) or CD (Figure [5b](#F5){ref-type="fig"}) or UC (Figure [5c](#F5){ref-type="fig"}) changed significantly when we omitted the study \[[@R16]\] by Latiano et al., suggesting that our data about rs1545620 polymorphism were poorly stable and trustworthy.

Both Egger\'s and Begg\'s tests were used to evaluated the publication bias of this meta-analysis. Our data revealed that there was no obvious publication bias in overall analysis for these five SNPs (Table [2](#T2){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"} and Figure [6](#F6){ref-type="fig"}). Due to limited studies, we did not conduct Egger\'s and Begg\'s tests in stratification analyses of ethnicity.

![Sensitivity analyses between the rs1545620 polymorphism and (a): IBD, (b): UC and (c): CD risk in allele model](oncotarget-07-58862-g005){#F5}

![Begg\'s tests for publication bias between (a): rs1545620, (b): rs962917, (c): rs1457092, (d): rs2305764 and (e): rs2305767 polymorphisms and the risk of IBD in dominant model](oncotarget-07-58862-g006){#F6}

DISCUSSION {#s3}
==========

In this meta-analysis, we evaluated recent studies on the relationships between *MY09B* gene polymorphisms and susceptibility to IBD, CD and UC. The primary findings were as follows: (1) the rs1545620 polymorphism was associated with a decreased risk of IBD; (2)rs2305767 decreased the risk of UC; (3) rs962917 increased the risk of IBD, CD and UC; (4) rs1457092 increased the risk of IBD and UC; (5) rs2305764 was associated with an increased risk of IBD; and (6) stratification analyses indicated that rs1545620 decreased the risk of IBD in Caucasian populations, while rs962917 increased the risk of IBD, CD and UC in Caucasian populations.

*MYO9B* is a candidate gene that is reportedly associated with celiac disease \[[@R10]\] and diabetes type 1 (DM type 1) \[[@R24], [@R25]\]. A previous study \[[@R26]\] demonstrated increased intestinal permeability in DM type 1 patients *in vivo*, which was associated with increased *MYO9B* gene expression. Their findings indicated a close link between *MYO9B* expression and changes in intestinal permeability \[[@R26]\]. MYO9B is a single motor protein with a Rho GTPase-activating domain, which downregulates Rho-dependent signaling pathways by converting active Rho-GTP into inactive Rho-GDP \[[@R9]\]. GTPases of the Rho family have been demonstrated to be involved in the regulation of tight junction function and actin filament remodeling, which lead to enhanced paracellular epithelial permeability \[[@R27], [@R28]\]. Therefore, it is reasonable to hypothesize that MYO9B may cause impaired intestinal barrier integrity. Furthermore, IBD is often characterized by increased permeability of intestinal epithelium \[[@R29], [@R30]\]. These findings suggest that MY09B may play an important role in the pathogenesis of IBD, and that *MY09B* is a candidate susceptibility gene for IBD.

To date, several studies have assessed associations between *MYO9B* gene polymorphisms and IBD susceptibility; however, they reported conflicting results. Several studies \[[@R14], [@R17], [@R19], [@R21]\] did not find *MYO9B* to be a candidate gene for IBD, while other studies \[[@R15], [@R16], [@R18], [@R20]\] suggested this gene was significantly associated with IBD, CD or UC risk. However, these studies had inadequate statistical power and involved relatively small samples. To overcome these limitations, we conducted a meta-analysis to assess associations between *MY09B* gene polymorphisms and the risk of IBD, CD and UC.

We determined that rs1545620 was associated with a decreased risk of IBD and rs2305767 was associated with a decreased risk of UC. Moreover, three other SNPs (rs962917, rs1457092 and rs2305764) increased the risk of IBD, CD or UC. It is noteworthy that only rs962917 was related to the risk of CD in this meta-analysis, while the four other SNPs were not. We found that rs1457092 and rs2305767 were associated with the risk of UC. Previous studies have demonstrated genetic differences between CD and UC \[[@R31]\]. Twin concordance rate data have indicated that the heritable component is less crucial for UC than for CD \[[@R32]\].A Spanish study \[[@R20]\] by Nunez et al. found that *MYO9B* gene polymorphisms were not correlated with CD, but were with UC. Van Bodegraven et al. reported that *MY09B* was more strongly associated with UC than with CD \[[@R18]\]. Furthermore, they found *MY09B* gene polymorphisms were not associated with CD in the Canadian/Italian populations \[[@R18]\]. It is therefore reasonable to assume that *MYO9B* may affect susceptibility to UC specifically. With regard to rs962917, only three studies \[[@R16], [@R17], [@R21]\] involving 1,500 cases and 2,005 controls addressed the association between this SNP and CD; however, these studies involved a smaller sample size compared with works focusing on the other four SNPs. Any association between SNPs in genes with diseases is greatly affected by the number of subjects. Given the small number of participants, we should interpret the relationship between rs962917 and CD with caution. Furthermore, the power of this meta-analysis about rs962917 polymorphism was smaller compared with other four polymorphisms. The power of rs1457092, rs2305764, rs2305767 and rs1545620 polymorphisms was greater than 0.95, which suggested that our data were trustworthy. Further studies on the role of *MY09B* in UC are warranted.

Analyses stratified by ethnicity indicated that rs1545620 decreased the risk of IBD in Caucasian populations. Our data also suggest that rs962917 increased the risk of IBD, CD and UC in Caucasian populations. However, a relationship between *MY09B* and IBD, CD or UC was not detected in Asian populations. The genetic background of IBD may vary among ethnicities. Previous studies have demonstrated *OCTN* or *CARD15* gene variations to be associated with susceptibility to CD in Caucasian populations \[[@R33], [@R34]\], but not in Asian populations \[[@R35]\]. Two Asian studies from China \[[@R17], [@R19]\] reported no associations between *MY09B* gene polymorphisms and IBD. Although Hu et al. revealed that *MYO9B* gene might influence the sub-phenotypic expression of CD, they did not find an association between these *MYO9B* polymorphisms and intestinal permeability in IBD \[[@R17]\]. It is intriguing to hypothesize that variations in *MYO9B* predispose Caucasians to IBD. However, we cannot definitively state that *MYO9B* is not related to IBD in Asian patients, because this meta-analysis included only two Chinese studies \[[@R17], [@R19]\] with limited sample sizes. Larger-scale studies are urgently needed to assess associations between *MYO9B* gene polymorphisms and IBD in Asian populations and other ethnicities.

Among all included studies, one Chinese study \[[@R17]\] did not conform to HWE with respect to the rs1545620 polymorphism. After excluding this study, the pooled estimates of the remaining studies indicated that the rs1545620 polymorphism might decrease the risk of IBD (Table [3](#T3){ref-type="table"}), consistent with the initial result. Heterogeneity was not reduced after exclusion of the Chinese study; it is thus tempting to speculate that this may not have been a source of heterogeneity. A sensitivity analysis of rs1545620 omitting the study by Latiano et al. \[[@R16]\] significantly altered the pooled ORs for the effect of this SNP on the risk of IBD, CD or UC, suggesting that the rs1545620 data are poorly reliable. It is noting that this study \[[@R16]\] did not provide the basic data of controls. We did not make sure whether the controls in this study were matched cases for age, sex or other confounders. As a result, we could not exclude the possibility that their results were false positive. The reasons why this study \[[@R16]\] affected the results of rs1545620 polymorphism remained unclear, but may be partially explained by above assumption. As for other reasons, clinical heterogeneity, and different ethnic populations may explain it, which needs further verification.

Several potential limitations of this meta-analysis should be taken into consideration. First, one Chinese study did not conform to HWE with respect to rs1545620 polymorphism; however, our data indicated the results of this SNP were trustworthy. Second, the numbers of studies included in the meta-analysis was small, and the sample size of this meta-analysis was not large enough. Third, our results were based on unadjusted estimates, without considering other confounders (such as age, gender, or environmental factors); thus, a more precise analysis should be performed, assuming the availability of individual data. Fourth, due to inclusion of only two Asian studies, we could not conduct analyses on rs1457092, rs2305764 or rs2305767 stratified by ethnicity. Future studies that include Asian populations and other ethnic groups are warranted due to ethnic differences in gene polymorphisms. Fifth, the heterogeneity of this meta-analysis was high in some genetic models.

In conclusion, this meta-analysis indicated that five SNPs within *MY09B* were associated with the risk of IBD, CD or UC. Future large-scale studies in Asian populations and other ethnicities are urgently needed to more accurately characterize associations between *MY09B* gene polymorphisms and IBD, CD and UC.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

We performed a comprehensive search in PubMed, Embase, and CNKI databases to identify studies through January 1, 2016 that were related with the *MY09B* gene polymorphisms and IBD, CD or UC. The following search terms were used: "inflammatory bowel disease," "IBD" "ulcerative disease," "UC," "Crohn\'s disease," "CD," "MYO9B," "myosin IXB" and "polymorphisms". Two independent authors conducted the search. No language or other restrictions were placed on the search. We also performed a manual search of references cited in published articles to identify other initially omitted studies. Any disagreements were resolved by consensus.

Criteria of inclusion and exclusion {#s4_2}
-----------------------------------

Criteria for the inclusion in this analysis were: (1) studies that evaluated the associations between UC or CD or IBD with at least one of the five single nucleotide polymorphisms (SNPs), (2) studied on human beings, (3) study provided sufficient data to calculate the Odds ratios (ORs) and 95% confidence intervals (CIs), and *P* value, and (4) case-control study. Exclusion criteria were: (1) duplication of previous publications; (2) review, editorial, or other non-original studies; (3) studies without detailed genotype data; (4) studies were without control group.

Data extraction and quality assessment {#s4_3}
--------------------------------------

For all eligible studies, the extracted information including: name of first author, publication year, country of origin, ethnicity, numbers of cases (UC and CD) and controls, and polymorphisms. Two authors independently performed the extraction of data and evaluated the study quality based on the Newcastle-Ottawa Scale (NOS) \[[@R36]\]. Total NOS scores ranged from 0 to 9. A score ranging 5 to 9 stars is considered to be a generally high methodological quality whereas a score ranging 0 to 4 is regarded as a relatively poor quality \[[@R37]\]. They compared results and agreed on a consensus; disagreements were resolved by discussion.

Statistical analysis {#s4_4}
--------------------

All statistical analyses were performed using the Stata 11.0 software (StataCorp, College Station, TX, USA). Pooled ORs and 95% CIs were calculated to assess the associations between UC or CD or IBD and the five polymorphisms of *MY09B* gene. *P* \< 0.05 was considered statistically significant. Heterogeneity was evaluated by the Q statistic (significant at *P* \< 0.1) and I^2^ statistic (where \> 50% indicates significant heterogeneity) \[[@R38]\]. A fixed-effect model was used for comparing the trials without showing heterogeneity, whereas a random effect model was selected for comparing trials showing heterogeneity. Pooled ORs were calculated for allele model, the dominant model, the recessive model and the homozygous model. We performed sensitivity analyses by omitting each study in turn to determine the effect on the test of heterogeneity and evaluated the stability of the overall results. Hardy-Weinberg equilibrium (HWE) was assessed in the controls using Pearson\'s χ^2^ test. Potential publication bias was investigated with the use of Begger\'s and Egger\'s linear regression test \[[@R39]\]; *P* \< 0.05 was considered to indicate statistically significant. The power of this meta-analysis for five SNPs was calculated according to the method recommended by Hedges and Pigott \[[@R40]\], with a significant value of 0.05. We calculated the FPRP of this meta-analysis based on the methods of Wacholder et al. \[[@R41]\] and preset an FPRP value of 0.5.

SUPPLEMENTARY TABLE {#s5}
===================
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IBD

:   inflammatory bowel disease

CD

:   Crohn\'s disease

UC

:   ulcerative colitis

MYO9B

:   Myosin IXB

CI

:   confidence interval

OR

:   odds ratio

NOS

:   Newcastle-Ottawa Scale

HWE

:   Hardy-Weinberg equilibrium
